The signing ceremony took place on the evening of 12/9, witnessed by Russian Health Minister Mikhail Murashko and Vietnamese Health Minister Dao Hong Lan. This follows VNVC's comprehensive cooperation agreement with the Russian Direct Investment Fund (RDIF) in May.

Under the agreement, the two entities will collaborate on research, development, production, and clinical trials of new drugs and vaccines. They will also distribute Medsintez's high-quality pharmaceutical products in Vietnam and the ASEAN region. The high-tech biopharmaceuticals to be transferred for production include: recombinant albumin, recombinant insulin; disposable and reusable insulin pens, diabetes treatments liraglutide and semaglutide; the anticoagulant heparin, the antiviral triazavirin, and follicle-stimulating hormone used in infertility treatment.

Konstantin Gorodnitsky, Head of Medsintez's Representative Office in Vietnam, and Tran Thi Hong Thuy, Director of VNVC's Vaccine and Biological Products Plant (top row), signed the cooperation agreement, witnessed by Russian Federation Health Minister Mikhail Murashko and Vietnamese Health Minister Dao Hong Lan. Photo: Pham Giang

Konstantin Gorodnitsky, Head of Medsintez's Representative Office in Vietnam, and Tran Thi Hong Thuy, Director of VNVC's Vaccine and Biological Products Plant (top row), signed the cooperation agreement, witnessed by Russian Federation Health Minister Mikhail Murashko and Vietnamese Health Minister Dao Hong Lan. Photo: Pham Giang

VNVC and Medsintez will also conduct joint clinical research on the antiviral drug triazavirin for treating dengue fever, potentially enhancing dengue fever prevention and control capabilities.

"By the end of 2027, the VNVC Vaccine and Biological Products Plant is expected to begin producing next-generation vaccines and advanced biopharmaceuticals from Russia and other countries", said Ngo Chi Dung, Chairman of the Board of Directors and General Director of the VNVC Vaccine and Biological Products Plant.

Speaking at the event, Vietnamese Health Minister Dao Hong Lan stated that healthcare is a key area of cooperation, demonstrating the special trust and bond between Russia and Vietnam in physician training, drug and vaccine supply, modern technology provision, and healthcare facility construction. She expressed hope that cooperation between research institutes and high-tech medical centers of the two countries will create new opportunities, particularly in cancer treatment and pharmaceutical production.

VNVC currently has a vaccination center network of nearly 240 facilities nationwide, administering tens of millions of doses of high-quality vaccines annually. VNVC's vaccine plant is already under construction and is expected to supply hundreds of millions of doses of vaccines and biological products each year when operational.

Previously, in 5/2025, VNVC signed a cooperation agreement with leading biotechnology partners, including the Gamaleya National Research Center of Epidemiology and Microbiology and the Binnopharm Pharmaceutical Group of Russia, to promote research, investment, technology transfer, and commercialization of biopharmaceuticals and high-tech vaccines, including mRNA cancer vaccines.

Medsintez is a leading Russian biotechnology pharmaceutical company with over 20 years of experience in research, development, and production of prescription drugs, medical devices, and pharmaceutical ingredients. With its extensive R&D and international-standard manufacturing capabilities, Medsintez is renowned for its global technology transfer programs.

Gia Nghi